oxaliplatin + cetuximab + bevacizumab + panitumumab + irinotecan + leucovorin + fluorouracil

This is a combination of chemotherapy agents and targeted therapies used in the treatment of metastatic colorectal cancer (mCRC). The combination includes cytotoxic chemotherapy agents (oxaliplatin, irinotecan, fluorouracil), anti-EGFR monoclonal antibodies (cetuximab, panitumumab), an anti-VEGF monoclonal antibody (bevacizumab), and a folate supplement (leucovorin). These agents are not typically administered simultaneously as a single regimen but are used in various combinations depending on treatment protocols, patient characteristics, and disease stage. The chemotherapy components work by interfering with DNA replication and cell division, while the targeted therapies block specific growth pathways in cancer cells. Anti-EGFR agents are only effective in patients with RAS wild-type tumors.